Adult Vaccine Market Global Forecast Report by Disease wise (Influenza, Cervical Cancer (HPV), Zoster (Shingles), MMR (Measles, Mumps, and Rubella Vaccine), Pneumococcal, Meningococcal, Hepatitis, Tdap, Travel and Miscellaneous, Varicella) Countries and Company Analysis, 2024-2032

It is advised that adults 65 years of age and above, as well as younger persons with specific health issues, have a pneumococcal vaccination to protect against the bacteria Streptococcus pneumoniae, which causes pneumonia, meningitis, and bloodstream infections. Adults 50 years of age and above should have a herpes zoster vaccination to avoid shingles, a painful rash brought on by the varicella-zoster virus. Adults up to the age of 26 are advised to have HPV vaccinations in order to guard against genital warts, anal, cervical, and other malignancies. The management of HCV infections and the avoidance of liver-related consequences depend heavily on developments in treatment and preventative methods, such as hepatitis A and B vaccinations. The right vaccination schedule for each person must be determined by speaking with healthcare professionals or public health authorities, as recommendations for vaccinations can change depending on age, health status, occupation, travel history, and other factors.

Many individuals in nations like the United States die each year from diseases that can be prevented by vaccination, according to the NCBI. In addition, the Centers for Disease Control (CDC) state that everyone has to get the influenza vaccine every year since it is especially important for older people, pregnant women, and those with chronic conditions. In order to prevent whooping cough, adults who have not previously received the Tdap (Tetanus, Diphtheria, and Pertussis) vaccination are advised by the CDC to receive it once. Every ten years, adults receive a booster shot against diphtheria and tetanus. Tdap vaccinations should also be administered to expectant mothers every 27 to 36 weeks of pregnancy.

Growth Factors in the Adult Vaccine Industry

Adult diseases are becoming more prevalent.

The global market for adult vaccines may rise as adult diseases become more commonplace worldwide. People are living longer because of enhanced medical facilities and altered lifestyles, which increases the risk of developing age-related diseases. Adults require periodic booster doses of immunizations to stay protected against diseases like pneumonia, shingles, hepatitis, and influenza that risk growing with age. In contrast, pediatric diseases are frequently preventable by routine vaccination programs. Even in industrialized nations, there are significant incidence and mortality rates of adult vaccine-preventable diseases, according to a number of reports from health agencies including the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC).

For example, the CDC's data indicates that during 2019–2020, influenza and its consequences led to over 75,000 hospital admissions and over 5,000 fatalities in the United States. Based on data released by the World Health Organization, Streptococcus pneumoniae continues to rank among the top 10 causes of death for older persons, accounting for an estimated 500,000 deaths annually. Moreover, according to United Nations estimates, one in six people worldwide will be older than 65 by 2030. Adults are more likely to develop chronic illnesses as well as infectious diseases due to this demographic transition and the rising incidence of non-communicable diseases.

For instance, in September 2023, 22 states in the United States had adult obesity rates at or over 35%, up from 19 states in 2021, according to the Centers for Disease Control and Prevention. This trend highlights the urgent need for population-wide treatments, such as programs that prevent and cure obesity without stigma, safe spaces for physical activity, and access to healthful foods. The information also shows differences between racial and ethnic groupings, highlighting the significance of focused health equity programs. Reducing the risk of chronic illnesses and enhancing general public health outcomes across the country depend on addressing obesity.

An increase in infectious disease transmission will highlight the expansion of the global market.

The prevalence of infectious diseases among adults is rising, and the government is taking more steps to encourage adult vaccine development, which will positively impact the trends in the adult vaccines market globally. Moreover, the government's growing partnerships with pharmaceutical and biopharmaceutical companies to produce innovative vaccines would positively impact the market's expansion in the next years. Additionally, it is anticipated that a breakthrough in the biomedical field will open doors for the future expansion of the worldwide industry. Furthermore, in the years to come, the proliferation of new product launches along with partnerships between government agencies and industry participants will boost global market expansion.

Furthermore, the global market for adult vaccines will expand in tandem with official clearance of vaccines in nations like the United States. For example, GSK plc announced in May 2023 that Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults 60 years of age and older, was licensed by the U.S. FDA to prevent lower respiratory tract illness in adults 60 years of age and older caused by respiratory syncytial virus.

North America Adult Vaccine Market Overview:

The market for adult vaccinations worldwide was dominated by the North American area. An increase in adult viral infection rates, especially in the US and Canada, may be the cause of this anticipated sustained leadership in the worldwide market.

An increase in adult viral infections is expected to drive a large growth in the North American market, highlighting the critical role that vaccination plays in disease prevention and lowering public health risks. In particular, the National Institutes of Health (NIH) discovered that the influenza vaccine by itself lowers the number of hospitalizations among older individuals in the US by almost 90,000 every year, highlighting the importance of vaccination in lowering healthcare costs.

Adults should regularly acquire immunizations against a variety of diseases, according to recommendations released by the US Centers for Disease Control and Prevention (CDC). All people should get vaccinated against seasonal influenza and tetanus, diphtheria, and pertussis (Tdap). In addition, the CDC recommends pneumococcal vaccination for individuals 65 years of age and above, as well as the herpes zoster vaccine for those over 50.

Adult Vaccine Market Company Overview

Some of the industry leaders seen in the Global Adult Vaccine Market Includes GlaxoSmithKline, plc., AstraZeneca plc, Sanofi Pasteur, Pfizer, Inc., CSL Limited.

Adult Vaccine Market News

In April 2024, Results from the Phase 3 trial STRIDE-10 were released by the pharmaceutical giant Merck at the 34th ESCMID Global in Barcelona, Spain. The trial evaluated Merck's adult-specific 21-valent pneumococcal conjugate vaccination, V116. It examined the safety, immunogenicity, and tolerability of V116 vs PPSV23, a 23-valent pneumococcal polysaccharide vaccine, in people 50 years of age and older who had not received a pneumococcal vaccination before.

In August 2022, Interim recommendations for the use of the Pfizer BioNTech (BNT162b2) vaccine against COVID-19 were released by the WHO Strategic Advisory Group of Experts on Immunization (SAGE). These are only some of the interim recommendations; the full guidance document is available here. The Pfizer-BioNTech COVID-19 mRNA vaccine is safe and effective, according to SAGE.

Disease Wise – Market breakup in 10 viewpoints:

1. Influenza                  
2. Cervical Cancer (HPV)                  
3. Zoster (Shingles)                  
4. MMR (Measles, Mumps, and Rubella Vaccine)                  
5. Pneumococcal                  
6. Meningococcal                  
7. Hepatitis                   
8. TdaP                  
9. Travel and Miscellaneous                  
10. Varicella

Country – Market breakup in 21 viewpoints:

North America

• United States
• Canada

Europe

• United Kingdom
• Germany
• France
• Russia
• Italy
• Spain
• Switzerland

Asia Pacific

• India
• China
• Japan
• Australia
• South Korea

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• Saudi Arabia
• United Arab Emirates
• South Africa

Rest of the World
 

All the Key players have been covered from 5 Viewpoints:

1. Overviews
2. Key Person
3. Recent Developments & Strategies
4. Product Portfolio & Product Launch in Last 1 Year
5. Revenue

Company Analysis:

1. GlaxoSmithKline, plc.
2. AstraZeneca plc
3. Sanofi Pasteur
4. Pfizer, Inc.
5. CSL Limited

Report Details: